PreveCeutical Medical Inc (TSE:PREV)
:PREV
Want to see TSE:PREV full AI Analyst Report?
Top Page
PreveCeutical Medical
(PREV)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.02
▼(-5.00% Downside)
Action:Reiterated
Date:05/06/26
The score is primarily weighed down by weak financial performance—no revenue, widening losses, rising cash burn, and a stressed balance sheet with negative equity and higher debt. Technical indicators are mostly neutral and provide limited offset, while valuation is constrained by ongoing losses and no dividend support.
Positive Factors
R&D and IP Pipeline
A clear emphasis on formulation, delivery platforms and early-stage therapeutic candidates with active IP progression provides durable optionality. Strong platform IP can enable licensing or partner commercialization, creating long-term value even before revenues emerge if patents and partnerships execute.
Negative Factors
No commercial revenue and persistent losses
No commercial revenue across multiple years means the business model remains unvalidated and dependence on R&D milestones or partners is high. Persistent, worsening losses erode capital, limit reinvestment capacity, and increase the probability of dilution or halted programs absent new funding or successful partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
R&D and IP Pipeline
A clear emphasis on formulation, delivery platforms and early-stage therapeutic candidates with active IP progression provides durable optionality. Strong platform IP can enable licensing or partner commercialization, creating long-term value even before revenues emerge if patents and partnerships execute.
Read all positive factors
PreveCeutical Medical (PREV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.74M
Dividend YieldN/A
Average Volume (3M)143.42K
Price to Earnings (P/E)―
Beta (1Y)-0.59
Revenue GrowthN/A
EPS Growth-36.36%
CountryCA
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding586,811,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PreveCeutical Medical Business Overview & Revenue Model
Company Description
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a canna...
How the Company Makes Money
null...
PreveCeutical Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.43K | -10.10K | -9.86K | -9.89K | -5.09K |
| EBITDA | -3.35M | -837.46K | -955.09K | -1.23M | -829.83K |
| Net Income | -1.58M | -1.17K | -1.27M | -1.48M | -1.73M |
Balance Sheet | |||||
| Total Assets | 1.45M | 225.66K | 181.51K | 189.14K | 161.20K |
| Cash, Cash Equivalents and Short-Term Investments | 10.24K | 59.14K | 1.43K | 5.62K | 16.06K |
| Total Debt | 4.68M | 4.46M | 3.83M | 3.23M | 2.93M |
| Total Liabilities | 7.69M | 6.86M | 5.96M | 4.82M | 4.27M |
| Stockholders Equity | -6.24M | -6.64M | -5.78M | -4.64M | -4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.72M | -428.49K | -296.97K | -222.64K | -481.59K |
| Operating Cash Flow | -1.72M | -426.69K | -296.97K | -222.64K | -426.39K |
| Investing Cash Flow | -2.96K | -1.80K | 0.00 | 850.00 | -52.70K |
| Financing Cash Flow | 1.68M | 487.64K | 293.62K | 211.72K | 136.75K |
PreveCeutical Medical Technical Analysis
Negative
0.02
Price Trends
0.02
Positive
0.02
Negative
0.03
Negative
Market Momentum
<0.01
Positive
48.98
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.98 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PREV.
PreveCeutical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$9.11M | -6.03 | 19.14% | ― | ― | 62.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$15.79M | -7.66 | -78.88% | ― | 125.00% | 25.37% | |
44 Neutral | C$11.74M | -8.98 | 21.59% | ― | ― | -36.36% | |
42 Neutral | C$13.85M | -4.62 | 75.85% | ― | 72.84% | 29.98% |
* Healthcare Sector Average
TSE:PREV
PreveCeutical Medical
0.02
>-0.01
-33.33%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.13
-55.32%
TSE:BETR
BetterLife Pharma
0.06
-0.05
-45.45%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.15
<0.01
7.41%
PreveCeutical Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
PreveCeutical Shifts to Semi-Annual Reporting Under CSE Pilot Program
Neutral
Apr 1, 2026
PreveCeutical Medical Inc., a health sciences company developing preventive and curative therapies from organic and nature-identical products, is advancing multiple RD programs, including dual gene therapies for metabolic diseases, peptide-based t...
Business Operations and StrategyExecutive/Board Changes
PreveCeutical Adds Veteran Clinical Leader Raj S. Pruthi to Board to Drive Pipeline Advancement
Positive
Mar 30, 2026
PreveCeutical Medical Inc., a health sciences company developing preventive and curative therapies based on organic and nature-identical products, has appointed Dr. Raj S. Pruthi to its Board of Directors. The company’s research programs inc...
Business Operations and StrategyExecutive/Board Changes
PreveCeutical-Backed BioGene Therapeutics Names Raj Pruthi to Board to Drive Gene Therapy Strategy
Positive
Mar 12, 2026
BioGene Therapeutics Inc., in which PreveCeutical Medical is a significant shareholder, has appointed Raj S. Pruthi, MD, MHA, FACS, as a director to lead its clinical strategy and advance its gene therapy programs for metabolic diseases including ...
Business Operations and Strategy
PreveCeutical Wins Key Canadian Patent Allowance for Next‑Generation Pain Therapy
Positive
Feb 26, 2026
PreveCeutical Medical has received a notice of allowance from the Canadian Patent Office for a patent covering novel cyclic peptide analogues of dynorphin, underpinning its pain therapy program. Jointly owned with The University of Queensland, the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.